218 related articles for article (PubMed ID: 28270555)
1. Dosage-dependent regulation of
Ruggiero C; Doghman-Bouguerra M; Sbiera S; Sbiera I; Parsons M; Ragazzon B; Morin A; Robidel E; Favier J; Bertherat J; Fassnacht M; Lalli E
Sci Signal; 2017 Mar; 10(469):. PubMed ID: 28270555
[TBL] [Abstract][Full Text] [Related]
2. Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.
Sbiera S; Sbiera I; Ruggiero C; Doghman-Bouguerra M; Korpershoek E; de Krijger RR; Ettaieb H; Haak H; Volante M; Papotti M; Reimondo G; Terzolo M; Luconi M; Nesi G; Mannelli M; Libé R; Ragazzon B; Assié G; Bertherat J; Altieri B; Fadda G; Rogowski-Lehmann N; Reincke M; Beuschlein F; Fassnacht M; Lalli E
J Clin Endocrinol Metab; 2017 Sep; 102(9):3491-3498. PubMed ID: 28911143
[TBL] [Abstract][Full Text] [Related]
3. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
[TBL] [Abstract][Full Text] [Related]
4. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
6. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
7. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
[TBL] [Abstract][Full Text] [Related]
8. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
9. Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults.
Almeida MQ; Soares IC; Ribeiro TC; Fragoso MC; Marins LV; Wakamatsu A; Ressio RA; Nishi MY; Jorge AA; Lerario AM; Alves VA; Mendonca BB; Latronico AC
J Clin Endocrinol Metab; 2010 Mar; 95(3):1458-62. PubMed ID: 20080844
[TBL] [Abstract][Full Text] [Related]
10. A reappraisal of transcriptional regulation by NR5A1 and beta-catenin in adrenocortical carcinoma.
Lalli E
Front Endocrinol (Lausanne); 2023; 14():1303332. PubMed ID: 38155952
[TBL] [Abstract][Full Text] [Related]
11. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
Gara SK; Wang Y; Patel D; Liu-Chittenden Y; Jain M; Boufraqech M; Zhang L; Meltzer PS; Kebebew E
Nucleic Acids Res; 2015 Oct; 43(19):9327-39. PubMed ID: 26446994
[TBL] [Abstract][Full Text] [Related]
12. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
13. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
14. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
Duregon E; Rapa I; Votta A; Giorcelli J; Daffara F; Terzolo M; Scagliotti GV; Volante M; Papotti M
Hum Pathol; 2014 Aug; 45(8):1555-62. PubMed ID: 24890943
[TBL] [Abstract][Full Text] [Related]
16. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
18. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
19. Steroidogenic Factor 1, a Goldilocks Transcription Factor from Adrenocortical Organogenesis to Malignancy.
Relav L; Doghman-Bouguerra M; Ruggiero C; Muzzi JCD; Figueiredo BC; Lalli E
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835002
[TBL] [Abstract][Full Text] [Related]
20. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
